Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-02-18Clinical Trial Update: A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma [Phase 1]
Phase 1 study of TAK-659 in combination with various agents for advanced non-Hodgkin lymphoma was terminated; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-02-17Clinical Trial Update: An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma [Phase 1, Phase 2]
This clinical trial update reports on the safety and effectiveness of combining Nivolumab and Daratumumab in patients with multiple myeloma …
-
CLINICAL_TRIALS trial_result · 2022-02-15Clinical Trial Update: T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma [Phase 1]
Phase 1 trial evaluating T cells engineered with fully-human anti-CD19 and anti-CD20 CARs for B-cell malignancies and Hodgkin lymphoma; the …
-
CLINICAL_TRIALS trial_result · 2022-01-27Clinical Trial Update: A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) [Phase 1, Phase 2]
Phase I/II study investigating CM355 in relapsed or refractory B-cell non-Hodgkin's lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-12-21Clinical Trial Update: Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A phase 1/2 clinical trial investigates a genetically engineered lymphocyte therapy given after peripheral blood stem cell transplant in pat…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-12-03Clinical Trial Update: Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating allogeneic CD19 CAR-T cells for relapsed/refractory B-cell lymphoma including non-Hodgkin lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-11-05Clinical Trial Update: Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating pralatrexate for relapsed or refractory B-cell non-Hodgkin's lymphoma has completed, with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-11-03Clinical Trial Update: A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma [Phase 3]
A Phase III randomized trial comparing low-dose versus standard-dose mBACOD chemotherapy with rGM-CSF for AIDS-associated non-Hodgkin lympho…
-
CLINICAL_TRIALS trial_result · 2021-10-04Clinical Trial Update: Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 study comparing Zevalin alone versus Zevalin with motexafin gadolinium in rituximab-refractory low-grade or follicular B-cell non-Ho…
-
CLINICAL_TRIALS trial_result · 2021-10-04Clinical Trial Update: Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT [Phase 1, Phase 2]
Clinical trial update on ex-vivo primed memory donor lymphocyte infusion to boost antiviral immunity after T-cell depleted hematopoietic ste…
-
CLINICAL_TRIALS trial_result · 2021-09-30Clinical Trial Update: Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies [Phase 1, Phase 2]
Clinical trial update on combining acalabrutinib (ACP-196) with ACP-319 for B-cell malignancies, including non-Hodgkin lymphoma, multiple my…
-
CLINICAL_TRIALS trial_result · 2021-09-28Clinical Trial Update: MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study [Phase 1]
Phase 1 study update for MEN1309 intravenous infusion in CD205-positive metastatic solid tumors and relapsed/refractory non-Hodgkin lymphoma…
-
CLINICAL_TRIALS trial_result · 2021-09-21Clinical Trial Update: Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
Clinical trial update for AMG 531 evaluating safety and efficacy in patients with Non-Hodgkin's Lymphoma across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2021-09-14Clinical Trial Update: A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL) [Phase 1]
Phase 1 trial of TAK-659 as a single agent in adult East Asian participants with various non-Hodgkin lymphoma subtypes was terminated.
-
CLINICAL_TRIALS trial_result · 2021-08-26Clinical Trial Update: Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma [Phase 1, Phase 2]
Clinical trial evaluating orelabrutinib in combination with thiotepa for refractory and relapsed primary CNS lymphoma (PCNSL) across Phase 1…
-
CLINICAL_TRIALS trial_result · 2021-08-25Clinical Trial Update: 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial updating the safety and preliminary efficacy of 10-Propargyl-10-Deazaaminopterin in recurrent or refractory lymphoma (non-Ho…
-
CLINICAL_TRIALS trial_result · 2021-08-19Clinical Trial Update: Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG [Phase 1, Phase 2]
Phase 1/2 trial update for 90Y-hLL2 IgG in Non-Hodgkin's Lymphoma shows completed status.
-
CLINICAL_TRIALS trial_result · 2021-08-18Clinical Trial Update: Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
A Phase 1/2 safety study evaluating different doses of hA20 (Veltuzumab) in CD20+ non-Hodgkin's lymphoma completed.
-
CLINICAL_TRIALS trial_result · 2021-08-17Clinical Trial Update: Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
Phase 1/2 study of hA20 (humanized anti-CD20) in CD20+ non-Hodgkin's lymphoma completed.
-
CLINICAL_TRIALS trial_result · 2021-08-16Clinical Trial Update: Safety Study of NHL With 90Y-hLL2 IgG [Phase 1, Phase 2]
A Phase 1/Phase 2 safety study of 90Y-hLL2 IgG in non-Hodgkin lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2021-08-16Clinical Trial Update: Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma [Phase 2, Phase 3]
Phase 2/Phase 3 trial evaluating monoclonal antibodies for detecting residual disease in patients treated for non-Hodgkin's lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-08-16Clinical Trial Update: Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL [Phase 1, Phase 2]
Clinical trial update for subcutaneously administered veltuzumab (hA20) in non-Hodgkin lymphoma and chronic lymphocytic leukemia; study comp…
-
CLINICAL_TRIALS trial_result · 2021-08-12Clinical Trial Update: Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) [Phase 2]
Phase 2 study of Tenalisib (RP6530), a dual PI3K δ/γ inhibitor, in relapsed/refractory indolent non-Hodgkin's lymphoma; study completed with…
-
CLINICAL_TRIALS trial_result · 2021-08-02Clinical Trial Update: A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating CD19/22 CAR-T cells combined with a PD-1 inhibitor in relapsed/refractory B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-08-02Clinical Trial Update: Study Evaluating Venetoclax in Subjects With Hematological Malignancies [Phase 1, Phase 2]
Clinical trial update for venetoclax in hematological malignancies at phases 1 and 2; study status completed.